• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-acting bronchodilator initiation in COPD and the risk of adverse cardio-pulmonary events: A population-based comparative safety study.
CONCLUSION: COPD treatment initiation with tiotropium compared with LABA does not increase cardiovascular risk in the first year of treatment. The risk of pneumonia is higher with LABA, a likely effect of the inhaled corticosteroids present in many LABA inhalers used in real world clinical practice. PMID: 27554300 [PubMed - as supplied by publisher]
Source: Chest - August 19, 2016 Category: Respiratory Medicine Authors: Suissa S, Dellaniello S, Ernst P Tags: Chest Source Type: research

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
In conclusion, the addition of a second long-acting bronchodilator in the real world setting treatment of COPD does not increase the risk of most cardiovascular events. The modest increase for heart failure may be due to residual confounding by indication and needs further investigation.
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Suissa, S., Dell'Aniello, S., Ernst, P. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research

Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Long-acting bronchodilators, including long-acting beta2-agonists (LABA) and the anticholinergic tiotropium, are recommended as initial maintenance treatment in COPD, though their risk on cardio-pulmonary events remains uncertain in real world settings. We assessed whether treatment initiation with tiotropium increases the risk of acute myocardial infarction (AMI), stroke, heart failure, arrhythmia and pneumonia, relative to a LABA.We identified all new users of a long-acting bronchodilator during 2002-2012, age 55 or older, from the United Kingdom's Clinical Practice Research Datalink. Each patient who initiated tiotropiu...
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Suissa, S., Dell'Aniello, S., Ernst, P. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research

Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination.
This study aimed to ascertain whether tiotropium/olodaterol (T/O) 5/5 μg fixed-dose combination (FDC) may modulate the risk of main cardiovascular outcomes in COPD patients enrolled in randomized controlled trials (RCTs). A meta-analysis (CRD42017070100) was performed by selecting RCTs reporting raw data from the ClinicalTrials.gov database concerning the impact of T/O 5/5 µg FDC vs. monocomponents on the occurrence of specific cardiovascular serious adverse events: arrhythmia, heart failure, myocardial infarction, and stroke. Data were reported as relative risk and 95% Confidence Interval, and the risk of publicatio...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - April 8, 2020 Category: Respiratory Medicine Tags: COPD Source Type: research